WallStSmart

Jaguar Animal Health Inc (JAGX)vsRevolution Medicines Inc (RVMD)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Jaguar Animal Health Inc generates 3649% more annual revenue ($27.82M vs $742,000). RVMD leads profitability with a 0.0% profit margin vs -130.8%. JAGX earns a higher WallStSmart Score of 31/100 (F).

JAGX

Avoid

31

out of 100

Grade: F

Growth: 2.7Profit: 2.0Value: 6.7Quality: 2.5
Piotroski: 3/9Altman Z: -19.59

RVMD

Avoid

24

out of 100

Grade: F

Growth: 3.7Profit: 3.0Value: 5.0Quality: 6.0
Piotroski: 1/9Altman Z: -0.99

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

JAGX1 strengths · Avg: 10.0/10
P/E RatioValuation
0.0x10/10

Attractively priced relative to earnings

RVMD1 strengths · Avg: 9.0/10
Debt/EquityHealth
0.259/10

Conservative balance sheet, low leverage

Areas to Watch

JAGX4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$3.77M3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Return on EquityProfitability
-411.6%2/10

ROE of -411.6% — below average capital efficiency

RVMD4 concerns · Avg: 3.5/10
Price/BookValuation
16.8x4/10

Trading at 16.8x book value

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Operating MarginProfitability
0.0%3/10

Operating margin of 0.0%

Comparative Analysis Report

WallStSmart Research

Bull Case : JAGX

The strongest argument for JAGX centers on P/E Ratio.

Bull Case : RVMD

The strongest argument for RVMD centers on Debt/Equity.

Bear Case : JAGX

The primary concerns for JAGX are EPS Growth, Market Cap, Piotroski F-Score. Debt-to-equity of 2.52 is elevated, increasing financial risk.

Bear Case : RVMD

The primary concerns for RVMD are Price/Book, EPS Growth, Profit Margin.

Key Dynamics to Monitor

JAGX profiles as a turnaround stock while RVMD is a value play — different risk/reward profiles.

RVMD carries more volatility with a beta of 1.41 — expect wider price swings.

JAGX is growing revenue faster at -58.9% — sustainability is the question.

JAGX generates stronger free cash flow (-5M), providing more financial flexibility.

Bottom Line

JAGX scores higher overall (31/100 vs 24/100). Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Jaguar Animal Health Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Jaguar Health, Inc., a commercial-stage pharmaceutical company, focuses on developing prescription drugs for people and animals with gastrointestinal upset, specifically chronic debilitating diarrhea. The company is headquartered in San Francisco, California.

Revolution Medicines Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.

Want to dig deeper into these stocks?